Immunocompetence, immunodeficiency and prognosis in cancer

Evan M Hersh, J. U. Gutterman, G. M. Mavligit

Research output: Contribution to journalArticle

48 Citations (Scopus)

Abstract

Immunocompetence and prognosis are related in solid tumors, malignant lymphomas, and acute leukemia. Among the parameters of immunocompetence vigorous delayed type hypersensitivity responses to recall antigens or to primary immunization with keyhole limpet hemocyanin, vigorous in vitro lymphocyte blastogenic responses to mitogens such as PHA, and relatively high B lymphocyte levels, all correlate with a good prognosis. The spectrum of immune reactivity as measured by established delayed type hypersensitivity (DTH) to recall antigens and in vitro blastogenic responses to mitogens and antigens is similar in melanoma patients and their nontumor bearing spouses. In melanoma, only patients with widespread inoperable metastatic disease show severe immunologic deficiency and this is selective for certain antigens. There are highly significant differences in response to specific antigens when patients with melanoma and lung cancer are compared. Immunotherapy with BCG and C. parvum can boost immunocompetence as measured by recall DTH skin testing. However, the relation between the initial immunocompetence and prognosis still holds in patients receiving BCG immunotherapy to prevent recurrence of melanoma. These data indicate that a broader survey of immunologic reactivity in cancer patients is needed, that immunologic testing is useful in cancer prognosis clinically, and that the results of immunological testing can be used to evaluate therapy and to indicate new pathways for improved treatment.

Original languageEnglish (US)
Pages (from-to)386-406
Number of pages21
JournalAnnals of the New York Academy of Sciences
VolumeVol. 276
StatePublished - 1976
Externally publishedYes

Fingerprint

Immunocompetence
Melanoma
Delayed Hypersensitivity
Antigens
Lymphocytes
Neoplasms
Mycobacterium bovis
Mitogens
Immunotherapy
Testing
Bearings (structural)
Immunization
Spouses
Tumors
Lymphoma
Lung Neoplasms
Skin
Leukemia
B-Lymphocytes
Cancer

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Immunocompetence, immunodeficiency and prognosis in cancer. / Hersh, Evan M; Gutterman, J. U.; Mavligit, G. M.

In: Annals of the New York Academy of Sciences, Vol. Vol. 276, 1976, p. 386-406.

Research output: Contribution to journalArticle

Hersh, Evan M ; Gutterman, J. U. ; Mavligit, G. M. / Immunocompetence, immunodeficiency and prognosis in cancer. In: Annals of the New York Academy of Sciences. 1976 ; Vol. Vol. 276. pp. 386-406.
@article{8e23c5b74d2547a7a48a87b1c182c44b,
title = "Immunocompetence, immunodeficiency and prognosis in cancer",
abstract = "Immunocompetence and prognosis are related in solid tumors, malignant lymphomas, and acute leukemia. Among the parameters of immunocompetence vigorous delayed type hypersensitivity responses to recall antigens or to primary immunization with keyhole limpet hemocyanin, vigorous in vitro lymphocyte blastogenic responses to mitogens such as PHA, and relatively high B lymphocyte levels, all correlate with a good prognosis. The spectrum of immune reactivity as measured by established delayed type hypersensitivity (DTH) to recall antigens and in vitro blastogenic responses to mitogens and antigens is similar in melanoma patients and their nontumor bearing spouses. In melanoma, only patients with widespread inoperable metastatic disease show severe immunologic deficiency and this is selective for certain antigens. There are highly significant differences in response to specific antigens when patients with melanoma and lung cancer are compared. Immunotherapy with BCG and C. parvum can boost immunocompetence as measured by recall DTH skin testing. However, the relation between the initial immunocompetence and prognosis still holds in patients receiving BCG immunotherapy to prevent recurrence of melanoma. These data indicate that a broader survey of immunologic reactivity in cancer patients is needed, that immunologic testing is useful in cancer prognosis clinically, and that the results of immunological testing can be used to evaluate therapy and to indicate new pathways for improved treatment.",
author = "Hersh, {Evan M} and Gutterman, {J. U.} and Mavligit, {G. M.}",
year = "1976",
language = "English (US)",
volume = "Vol. 276",
pages = "386--406",
journal = "Annals of the New York Academy of Sciences",
issn = "0077-8923",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Immunocompetence, immunodeficiency and prognosis in cancer

AU - Hersh, Evan M

AU - Gutterman, J. U.

AU - Mavligit, G. M.

PY - 1976

Y1 - 1976

N2 - Immunocompetence and prognosis are related in solid tumors, malignant lymphomas, and acute leukemia. Among the parameters of immunocompetence vigorous delayed type hypersensitivity responses to recall antigens or to primary immunization with keyhole limpet hemocyanin, vigorous in vitro lymphocyte blastogenic responses to mitogens such as PHA, and relatively high B lymphocyte levels, all correlate with a good prognosis. The spectrum of immune reactivity as measured by established delayed type hypersensitivity (DTH) to recall antigens and in vitro blastogenic responses to mitogens and antigens is similar in melanoma patients and their nontumor bearing spouses. In melanoma, only patients with widespread inoperable metastatic disease show severe immunologic deficiency and this is selective for certain antigens. There are highly significant differences in response to specific antigens when patients with melanoma and lung cancer are compared. Immunotherapy with BCG and C. parvum can boost immunocompetence as measured by recall DTH skin testing. However, the relation between the initial immunocompetence and prognosis still holds in patients receiving BCG immunotherapy to prevent recurrence of melanoma. These data indicate that a broader survey of immunologic reactivity in cancer patients is needed, that immunologic testing is useful in cancer prognosis clinically, and that the results of immunological testing can be used to evaluate therapy and to indicate new pathways for improved treatment.

AB - Immunocompetence and prognosis are related in solid tumors, malignant lymphomas, and acute leukemia. Among the parameters of immunocompetence vigorous delayed type hypersensitivity responses to recall antigens or to primary immunization with keyhole limpet hemocyanin, vigorous in vitro lymphocyte blastogenic responses to mitogens such as PHA, and relatively high B lymphocyte levels, all correlate with a good prognosis. The spectrum of immune reactivity as measured by established delayed type hypersensitivity (DTH) to recall antigens and in vitro blastogenic responses to mitogens and antigens is similar in melanoma patients and their nontumor bearing spouses. In melanoma, only patients with widespread inoperable metastatic disease show severe immunologic deficiency and this is selective for certain antigens. There are highly significant differences in response to specific antigens when patients with melanoma and lung cancer are compared. Immunotherapy with BCG and C. parvum can boost immunocompetence as measured by recall DTH skin testing. However, the relation between the initial immunocompetence and prognosis still holds in patients receiving BCG immunotherapy to prevent recurrence of melanoma. These data indicate that a broader survey of immunologic reactivity in cancer patients is needed, that immunologic testing is useful in cancer prognosis clinically, and that the results of immunological testing can be used to evaluate therapy and to indicate new pathways for improved treatment.

UR - http://www.scopus.com/inward/record.url?scp=0017102975&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0017102975&partnerID=8YFLogxK

M3 - Article

C2 - 800324

AN - SCOPUS:0017102975

VL - Vol. 276

SP - 386

EP - 406

JO - Annals of the New York Academy of Sciences

JF - Annals of the New York Academy of Sciences

SN - 0077-8923

ER -